跳至主要内容
临床试验/NCT02226068
NCT02226068已完成不适用

Ciclosporine and Extracorporal Photopheresis (ECP) Are Equipotent in Treating Severe Atopic Dermatitis (AD): A Randomized Cross-over Study Comparing Two Efficient Treatment Modalities

University of Aarhus0 个研究点目标入组 20 人开始时间: 2002年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
20
主要终点
Change of SCORAD (SCORing Atopic Dermatitis)

研究概览

简要总结

Severe atopic dermatitis (AD) is a recurrent and debilitating disease often requiring systemic immunosuppressive treatment. The efficacy of cyclosporine A (CsA) is well proven but potential side effects are concerning. Several reports point at extracorporeal photopheresis (ECP) as an efficient alternative treatment modality with few and mild side effects. However, no direct comparison between CsA and ECP in the treatment of AD has been performed so far. In this trial we test the hypothesis that ECP is non-inferior to standard treatment with CsA.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Criteria of inclusion were refractoriness to standard topical treatment (corticosteroid ointments, UVA, UVB, PUVA, tar).

排除标准

  • Criteria of exclusion were pregnancy, uncontrolled hypertension, previous malignancy, infectious disease, liver/kidney disease or active treatment with ECP or immunosuppressants within 4 weeks prior to start of trial.

研究组 & 干预措施

CsA-ECP

Other

Sequence of therapy: First ciclosporin was given and after relapse extra corporal photopheresis was given

干预措施: Cyclosporine A (CsA) (Drug)

CsA-ECP

Other

Sequence of therapy: First ciclosporin was given and after relapse extra corporal photopheresis was given

干预措施: Extracorporeal photopheresis (ECP) (Other)

ECP-CsA

Other

Sequence of therapy: First extra corporal photopheresis was given and after relapse ciclosporin was given

干预措施: Cyclosporine A (CsA) (Drug)

ECP-CsA

Other

Sequence of therapy: First extra corporal photopheresis was given and after relapse ciclosporin was given

干预措施: Extracorporeal photopheresis (ECP) (Other)

结局指标

主要结局

Change of SCORAD (SCORing Atopic Dermatitis)

时间窗: 4 month

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验